Lumosity Improves Overall Cognition in Randomized Clinical Trial Enrolling 801 Adults
Twelve weeks of at-home brain training outperformed an active control on a 12-test cognitive battery, and 70% of participants who trained with Lumosity said their thinking had improved
BOSTON, November 16, 2026 — Lumosity, the brain training program from Lumos Labs, improved overall cognition in healthy adults in a large randomized clinical trial. Results from the BRIGHT-Mind study will be presented at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston on Wednesday, November 18, 2026. The study enrolled 801 adults aged 25 to 80, who trained at home for 12 weeks with either Lumosity or a comparison program of educational videos. Among the 677 participants in the primary analysis, those who trained with Lumosity improved more on a separate 12-test cognitive battery (p = 0.00032).
Key findings
- Overall cognition: The Lumosity group improved more than the comparison group. The difference was about the size of the gap in test scores between participants roughly 6.7 years apart in age.
- All ages: The cognitive benefit was similar across ages 25 to 80.
- Participant-rated improvement: On the Patient Global Impression of Improvement (PGI-I), 70% of the Lumosity group reported improvement in concentration, memory and ability to think clearly, compared with 46% of the comparison group (p < 0.0001).
- Daily life: On the Sheehan Disability Scale (SDS), Lumosity participants reported greater cognition-related functional improvement than the comparison group on an overall measure including work or school, social life and home responsibilities (p = 0.00080).
- Brain structure in adults 60 to 80: The brain-predicted age difference changed about 1.5 years more favorably with Lumosity than with the comparison program. Further analyses found less enlargement of the ventricles and greater cortical thickness in regions tied to attention and cognitive control.
- Safety: No adverse events related to either program were reported.
“People should expect more from brain training than getting better at a game. That’s why we designed BRIGHT-Mind to put Lumosity to a rigorous test, with a comparison group that was also mentally engaged and cognitive tests participants had never practiced,” said Bob Schafer, PhD, CEO of Lumos Labs and corresponding author. “The results are encouraging evidence that training with Lumosity can improve performance on cognitive tests beyond the games themselves.”
The comparison group also spent time each day on a mentally engaging computer activity. This active-control design helps account for the possibility that the results reflected general engagement or expectations rather than the training itself. The cognitive benefit was similar across ages 25 to 80. The difference between groups was contextually meaningful, about the size of the gap in test scores between participants roughly 6.7 years apart in age.
Improvements people noticed in daily life
Participants also rated their own change on two measures widely used in drug trials and other clinical research. On the Patient Global Impression of Improvement (PGI-I), which asked how their concentration, memory and ability to think clearly had changed, 70% of the Lumosity group reported improvement, compared with 46% of the comparison group (p < 0.0001). On the Sheehan Disability Scale (SDS), Lumosity participants reported greater cognition-related functional improvement on an overall measure including work or school, social life and home responsibilities (p = 0.00080).
Training took about 15–25 minutes a day, at least five days a week. Of all participants assigned to Lumosity, 83.6% completed at least 13 hours of training over the 12 weeks.
Promising MRI findings in adults over 60
A subgroup of participants had MRI brain scans before and after the study. Across 220 evaluable participants, a prespecified analysis tested whether brain training affected how their MRI-based brain age compares with their actual age. Among participants aged 60 to 80, the brain-predicted age difference changed about 1.5 years more favorably with Lumosity than with the comparison program.
Deeper follow-up analyses of specific brain regions in the older participants helped describe the pattern. The largest differences were in the brain’s ventricles, the fluid-filled spaces that expand as brain tissue is lost with age. The ventricles enlarged less with Lumosity than with the comparison program. Cortical thickness was better maintained with Lumosity in the anterior cingulate cortex, middle temporal gyrus and prefrontal cortex, regions that support attention and cognitive control and are sensitive to aging.
“Behavioral and lifestyle interventions don’t always produce changes that show up on MRI, even when they improve cognition, but in the BRIGHT-Mind study, we saw differences in brain structure in older adults after only 12 weeks,” said Kelly MacNiven, research scientist and study co-author. “What’s notable is that the brain-age, ventricle and cortical-thickness results in participants 60 and older all told a consistent story.”
Questions for future studies
Because the trial enrolled healthy adults, the results don’t address whether these same findings apply to people with cognitive impairment or other neurological or psychiatric conditions. The trial also ran for 12 weeks; longer studies are needed to understand how effects are maintained with continued brain training or lost after stopping.
The MRI brain-predicted age difference analysis was planned in advance. The detailed analyses of ventricle volumes and cortical thickness in older participants were exploratory and should motivate future research. Participant-reported outcomes were also exploratory.
“The brain is where longevity becomes personal. As a clinician focused on brain health and aging, I’m interested in effective, engaging and safe approaches that can reach people where they are,” said Murali Doraiswamy, MBBS, FRCP, Professor in Psychiatry and Neurology at Duke University and a Lumos Labs Scientific Advisor. He added, “BRIGHT-Mind suggests that accessible, at-home cognitive training deserves serious attention as part of a broader approach to brain health.”
Presentation details
Poster P195: BRIGHT-Mind Study: A Prospective, Randomized Trial of Digital Cognitive Training Effects on Cognitive, Functional and Imaging Outcomes
Poster Session 2, Non-Pharmacologic Interventions
Wednesday, November 18, 2026, 7:15 a.m. – 5:30 p.m. ET
About the BRIGHT-Mind study
BRIGHT-Mind (Brain Response to an Intervention using Guided, at-Home Technology for the Mind) was a randomized, masked, active-controlled trial that enrolled 801 generally healthy adults living in 44 US states. Participants were randomized 2:1 to Lumosity or an educational-videos program for 12 weeks.
The primary endpoint was change in the Overall Composite score from a 12-test Creyos neurocognitive battery. Secondary endpoints included MRI brain-predicted age difference and cognitive domain scores; exploratory endpoints included participant-reported outcomes. The primary analysis included 677 participants. The trial was registered before enrollment (NCT05912556). Lumos Labs funded the study. Authors include current and former Lumos Labs employees and researchers from Duke University, UC Davis and Smith College.
To learn more about the study or download the poster, please visit www.lumosity.com/science/bright-mind.
About Lumos Labs
Lumos Labs, the creator of Lumosity, is a pioneer in cognitive health and digital medicine with the mission of empowering everyone to discover what their mind can do. The company's Lumosity program has attracted over 120 million members from 180+ countries, contributing to a dataset of over 9 billion cognitive games played, which serves to support over 200 collaborations with university research groups. Lumos Labs’ medical division is at the forefront of developing FDA-cleared digital medicine. Awarded by the Future of Privacy Forum for Data Stewardship, Lumos Labs prides itself on supporting the advancement of cognitive research while protecting the privacy of its members. For more information, visit: https://www.lumoslabs.com/
Media contact
Erica Perng, press@lumoslabs.com